Himalaya Therapeutics

Himalaya Therapeutics is a clinical-stage therapeutic company focused on developing innovative and differentiated therapies in Greater China and globally. The product portfolio includes two CAB candidates: AXL-targeted antibody-drug conjugate (CAB-AXL-ADC) and ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Both drugs are currently in Phase 1/2 clinical studies being conducted by BioAtla in the United States.